reference scaled bioequivalence [RSABE / ABEL]

posted by AngusMcLean – USA, 2010-11-07 15:55 (5715 d 02:22 ago) – Posting: # 6111
Views: 19,747

Sunday November 7, 201:

I discovered this slide from a presentation from Pharsight

From: 80-125% to ± 1.25σ(Ref)/0.25I understand it is an interpretation of the direction of FDA thinking relating to extending the criteria for means ratio and confidence intervals for BE of highly variable drugs.;-)

The observed ratio must be within 80-125%; the study design must be partially or fully replicated.

What do you think of it?

Angus


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
412 visitors (0 registered, 412 guests [including 15 identified bots]).
Forum time: 19:18 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5